��������

The long-acting monoclonal antibody nirsevimab was  to be 80% effective at preventing respiratory syncytial virus-associated intensive care unit admissions during the 2024-2025 RSV season,  to a recent Centers for Disease Control and Prevention report. It also found the treatment to be 83% effective at preventing acute respiratory failure among infants admitted to an ICU with symptoms during their first RSV season. “These data support recommendations to use nirsevimab as a prevention strategy to protect infants from severe outcomes from RSV infection,” the CDC said. (AHA News , 11/20/25)